Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
N Albinger, J Hartmann, E Ullrich - Gene therapy, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful
immunotherapeutic tools for combating hematological diseases confronted with pressing …
immunotherapeutic tools for combating hematological diseases confronted with pressing …
Emerging phagocytosis checkpoints in cancer immunotherapy
Cancer immunotherapy, mainly including immune checkpoints-targeted therapy and the
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
adoptive transfer of engineered immune cells, has revolutionized the oncology landscape as …
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape
Trogocytosis is an active process that transfers surface material from targeted to effector
cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen …
cells. Using multiple in vivo tumor models and clinical data, we report that chimeric antigen …
[HTML][HTML] Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma
MA Dimopoulos, D Dytfeld, S Grosicki… - … England Journal of …, 2018 - Mass Medical Soc
Background The immunostimulatory monoclonal antibody elotuzumab plus lenalidomide
and dexamethasone has been shown to be effective in patients with relapsed or refractory …
and dexamethasone has been shown to be effective in patients with relapsed or refractory …
[HTML][HTML] Elotuzumab therapy for relapsed or refractory multiple myeloma
S Lonial, M Dimopoulos, A Palumbo… - … England Journal of …, 2015 - Mass Medical Soc
Background Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling
lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with …
lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with …
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
S Prommersberger, M Reiser, J Beckmann, S Danhof… - Gene therapy, 2021 - nature.com
Clinical development of chimeric antigen receptor (CAR)-T-cell therapy has been enabled
by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and …
by advances in synthetic biology, genetic engineering, clinical-grade manufacturing, and …
Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
Chimeric antigen receptor (CAR)-T cell therapy has shown remarkable clinical efficacy
against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse …
against B-cell malignancies, yet marked vulnerability to antigen escape and tumor relapse …
Drug resistance in multiple myeloma
Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …
Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
Despite enormous advances, management of multiple myeloma (MM) remains challenging.
Multiple factors impact the decision to treat or which regimen to use at MM …
Multiple factors impact the decision to treat or which regimen to use at MM …
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Prolonging overall survival (OS) remains an unmet need in relapsed or refractory multiple
myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide …
myeloma (RRMM). In ELOQUENT-2 (NCT01239797), elotuzumab plus lenalidomide …